Timmerman Report is an independently-owned subscription publication that provides timely, in-depth biotech news and analysis. It’s for anyone who seeks to understand new drug development, diagnostics, genomics, and other technologies that are changing medicine.
I’m looking for the true innovations, the emerging trends, the market forces, and the characters at work. Because I’ve been covering the industry for more than a decade—through two busts and one and a half booms—I bring context to stories that few can match. Readers should expect big picture perspective, and a steady drumbeat of news, features, and original commentary.
This type of in-depth reporting will help prepare you for your next big meeting, find a partner, jump on an investment opportunity, hire an up-and-comer, get to know the people you work with, or land a job.
My goal is to write accessibly for all of you: in a way that specialized readers can appreciate and lay readers can understand. It’s the sort of clear, probing and contextual journalism that never goes out of style.
I look forward to serving you, the biotech reader, for years to come.
I focus on science, technology, medical evidence, regulatory issues and business strategy. I study how these things affect all kinds of organizations—everything from startups on their first $1 million to academic institutions to established companies. Subjects range from cancer to Alzheimer’s to genetic diseases and conditions that scientists are only beginning to adequately define.
Yes. This license grants companies with five or more subscribers the right to share copyrighted Timmerman Report content in-house. Groups can get a 10 percent discount off the regular rate of $149 per subscriber per year. Universities can get bigger discounts. Interested in a group license? email@example.com
2-3 stories per week.
You’ll get an e-mail when the story is published.
Memberful is the paywall software provider, and Stripe is the payment processing vendor.
No. As long as your web browser allows cookies, you will be automatically signed in every time you come to Timmerman Report. If you want to sign in on a second device, like a tablet or smartphone, then you will have to sign in once on that device, too.
Timmerman Report Gives You In-Depth Reporting on Biotech. Get Your Edge.
Corporate groups: luke (at) timmermanreport.com
Timmerman is always ahead of the game.
Today’s biotech social media is a firehose of data, information, and speculation. The savvy professional needs less noise and more actionable signal. Luke Timmerman finds and writes about that signal.
Luke’s ability to blend the implications of science with the exigencies of business creates an idiosyncratic and insightful read.
Meryl Schenker Photography
Luke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Before founding Timmerman Report in 2015, Luke wrote about the industry for a regional newspaper (The Seattle Times), a global financial publication (Bloomberg News), and an online startup (Xconomy). Luke’s first book, “Hood: Trailblazer of the Genomics Age” was called a “must-read” by Forbes, and named one of the “100 Best Indie Books of 2017” by Kirkus Reviews.
Luke was named one of the 100 Most Influential People in Biotechnology by Scientific American in 2015. He has won a number of journalism prizes, including the Scripps Howard National Journalism Award, the Association of Health Care Journalists Award, and the Society of American Business Editors and Writers (SABEW) award. Luke received his bachelor’s degree in journalism from the University of Wisconsin-Madison in 1997. For the 2005-2006 academic year, he was awarded a Knight Science Journalism Fellow at MIT.
Outside of work, Luke enjoys running, family camping trips, and mountaineering. He reached the summit of Mt. Everest, the highest mountain in the world at 29,029 feet/8,848 meters, on May 22, 2018. Luke’s Climb to Fight Cancer campaigns have raised $2.3 million for cancer research at Fred Hutch. He lives in Seattle with his wife and daughter.